Cue Biopharma
Cue Biopharma's Overview
Cue Biopharma (NASDAQ: CUE) is a clinical-stage biopharmaceutical company dedicated to engineering a novel class of injectable biologics, known as Immuno-STATs™ (Selective Targeting and Alteration of T cells). These innovative therapies are designed to selectively engage and modulate the activity of disease-relevant T cells directly within the patient's body. The company's proprietary platform aims to harness the body's immune system with precision to treat a wide range of cancers and autoimmune diseases, offering the potential for enhanced efficacy and improved safety profiles compared to broader immunotherapies. Cue Biopharma's lead oncology candidate, CUE-101, is currently in clinical development for HPV-driven cancers, with other programs targeting different antigens and disease areas progressing through their pipeline.
Where is Cue Biopharma's Headquarters?
HQ Function
Serves as the central hub for all corporate operations, research and development activities, clinical program management, and strategic leadership.
Notable Features:
Equipped with modern laboratory facilities essential for biologic drug discovery, protein engineering, immunological research, and process development. Its location within the Greater Boston biotech ecosystem provides strategic advantages.
Work Culture:
Fosters a highly collaborative, science-driven, and innovative environment. Employees are typically focused on cutting-edge research and development with a shared goal of bringing impactful therapies to patients. Emphasis is placed on teamwork, scientific rigor, and adaptability.
HQ Significance:
The Lexington headquarters is critical for Cue Biopharma's execution of its scientific and clinical strategy. It houses the core infrastructure and talent necessary for advancing its Immuno-STAT™ platform and pipeline candidates.
Values Reflected in HQ: The headquarters' setup, with its emphasis on advanced R&D labs, reflects the company's commitment to scientific innovation, precision in drug development, and the pursuit of therapeutic breakthroughs.
Location:
Cue Biopharma's operational headquarters are based in the United States. Their global reach is primarily established through their clinical trial operations, which may involve sites and investigators in North America and potentially other regions to ensure diverse patient enrollment for their therapeutic candidates. The company also engages with the international scientific and medical community through publications, conferences, and potential collaborations to advance its Immuno-STAT™ platform globally.
Street Address:
128 Spring Street, Suite 520
City:
Lexington
State/Province:
MA
Country:
USA
Cue Biopharma's Global Presence
Buying Intent Signals for Cue Biopharma
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Cue Biopharma
As of April 2025, Cue Biopharma' leadership includes:
Investors of Cue Biopharma
Cue Biopharma has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Over the past 12 months, Cue Biopharma has experienced notable changes in its executive team, including the appointment of a new Chief Financial Officer, the departure of its President and Chief Scientific Officer, followed by the appointment of an Acting Chief Scientific Officer, and an internal transition resulting in a new Chief Operating Officer.
Departures
New Appointments:
Technology (Tech Stack) used by Cue Biopharma
Discover the tools Cue Biopharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cue Biopharma Email Formats and Examples
Cue Biopharma likely uses standard corporate email address formats. A common pattern is the first initial of the first name followed by the last name, or the full first name followed by the last name, at the company's domain.
firstinitiallast@cuebiopharma.com (e.g., jdoe@cuebiopharma.com)
Format
dpasseri@cuebiopharma.com
Example
75%
Success rate
News and media
GlobeNewswire • May 8, 2024
Cue Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Cue Biopharma announced its Q1 2024 financial results and provided updates on its clinical programs, including progress with CUE-101 and CUE-102. The company also noted strategic pipeline prioritization and leadership changes....more
GlobeNewswire • April 2, 2024
Cue Biopharma Presents Promising Updated Clinical Data from Ongoing Phase 1b Monotherapy and Combination Trials of CUE-101 at the American Association for Cancer Research (AACR) Annual Meeting 2024
Cue Biopharma shared positive updated clinical data from its Phase 1b trials of CUE-101 in HPV16+ head and neck cancer, both as a monotherapy and in combination with pembrolizumab, at the AACR 2024 conference. The data highlighted encouraging anti-tumor activity and a manageable safety profile....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Cue Biopharma, are just a search away.